Integrated Filing — IndAS



General information about company

Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 06-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 06-11-2025   13:00:00
End date and time of board meeting 06-11-2025   18:05:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 11-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.lupin.com/wp-content/uploads/2025/03/policy-on-related-party-transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on Loans and Debt Securities is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 4,06,828.00 9,77,687.00
Other income 7,000.00 12,414.00
Total income 4,13,828.00 9,90,101.00
2 Expenses
(a) Cost of materials consumed 86,414.00 1,77,328.00
(b) Purchases of stock-in-trade 30,968.00 62,161.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 9,544.00 5,569.00
(d) Employee benefit expense 60,883.00 1,25,272.00
(e) Finance costs 2,778.00 4,668.00
(f) Depreciation, depletion and amortisation expense 17,472.00 35,145.00
(f) Other Expenses
1 Other expenses 1,21,486.00 2,41,705.00
2 Net (gain) / loss on foreign currency transactions (20,030.00) (24,875.00)
Total other expenses 1,01,456.00 2,16,830.00
Total expenses 3,09,515.00 6,26,973.00
3 Total profit before exceptional items and tax 1,04,313.00 3,63,128.00
4 Exceptional items 59,268.00 59,268.00
5 Total profit before tax 1,63,581.00 4,22,396.00
6 Tax expense
7 Current tax 28,723.00 73,877.00
8 Deferred tax (877.00) (23.00)
9 Total tax expenses 27,846.00 73,854.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,35,735.00 3,48,542.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,35,735.00 3,48,542.00
17 Other comprehensive income net of taxes (1,572.00) (1,771.00)
18 Total Comprehensive Income for the period 1,34,163.00 3,46,771.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 9,136.00 9,136.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 29.72 76.32
Diluted earnings (loss) per share from continuing operations 29.65 76.12
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 29.72 76.32
Diluted earnings (loss) per share from continuing and discontinued operations 29.65 76.12
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 06 2025. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015. 2. During the quarter ended September 30 2025 41745 year to date 192823 equity shares of Rs. 2 each fully paidup were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs resulting in an increase in the paidup equity share capital by Rs. 0.1 million year to date Rs. 0.4 million and securities premium account by Rs. 69.5 million year to date Rs. 215.6 million. 3. As approved by the Members of the Company at the 43rd Annual General Meeting held on August 11 2025 the Company has disbursed on August 14 2025 a final dividend of Rs. 12 per equity share of the face value of Rs. 2 each aggregating Rs. 5481.0 million. 4. Exceptional items a. During the quarter and six months ended September 30 2025 the Company transferred its Over the Counter OTC and API RandD business in India to its wholly owned subsidiary Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively as a going concern on slump sale basis for a consideration of Rs. 8200.0 millionand Rs. 180.0 million resulting in gain on divestment of Rs. 6589.6 million and Rs. 37.2 million respectively subject to working capital adjustments. b. During the quarter and six months ended September 30 2025 the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 700.0 million. During the year ended March 31 2025 the Company had provided for diminution in the value of investments in subsidiaries of Rs. 772.2 million. 5. During the quarter ended September 30 2024 the Company has transferred its generic business in India to its wholly owned subsidiary Lupin Life Sciences Limited formerly known as Lupin Atharv Ability Limited as a going concern on slump sale basis resulting in loss on divestment of Rs. 6.4 million. 6. During the year ended March 31 2025 the Company has made a provision of Rs. 856.1 million USD 10.0 million towards ongoing dispute. 7. During the six months ended September 30 2024 and year ended March 31 2025 Lupin Limited and its subsidiary agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing with a view to avoid the costs and uncertainties of continued litigation. 8. During the year ended March 31 2025 the Company has recognised an impairment charge of Rs. 410.9 million related to property plant and equipment commercialised intangibles and capital work in progress.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,39,620.00
Capital work-in-progress 32,192.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 1,09,871.00
Intangible assets under development 5,601.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 10,95,147.00
Trade receivables, non-current 0.00
Loans, non-current 12,785.00
Other non-current financial assets 5,814.00
Total non-current financial assets 11,13,746.00
Deferred tax assets (net) 0.00
Other non-current assets 54,253.00
Total non-current assets 16,55,283.00
2 Current assets
Inventories 3,39,957.00
Current financial asset
Current investments 3,14,678.00
Trade receivables, current 6,74,874.00
Cash and cash equivalents 15,847.00
Bank balance other than cash and cash equivalents 21,945.00
Loans, current 10,442.00
Other current financial assets 1,51,412.00
Total current financial assets 11,89,198.00
Current tax assets (net) 0.00
Other current assets 81,702.00
Total current assets 16,10,857.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 32,66,140.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,136.00
Other equity 27,13,334.00
Total equity attributable to owners of parent 27,22,470.00
Non controlling interest
Total equity 27,22,470.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 28,725.00
Total non-current financial liabilities 28,725.00
Provisions, non-current 41,998.00
Deferred tax liabilities (net) 14,554.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 17,467.00
Total non-current liabilities 1,02,744.00
Current liabilities
Current financial liabilities
Borrowings, current 70,638.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 10,021.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,01,493.00
Total Trade payable 2,11,514.00
Other current financial liabilities 49,668.00
Total current financial liabilities 3,31,820.00
Other current liabilities 35,846.00
Provisions, current 17,611.00
Current tax liabilities (Net) 55,649.00
Deferred government grants, Current 0.00
Total current liabilities 4,40,926.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 5,43,670.00
Total equity and liabilites 32,66,140.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss 1,963.00 928.00
Total Amount of items that will not be reclassified to profit and loss 1,963.00 928.00
2 Income tax relating to items that will not be reclassified to profit or loss 686.00 324.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss (4,379.00) (3,651.00)
Total Amount of items that will be reclassified to profit and loss (4,379.00) (3,651.00)
4 Income tax relating to items that will be reclassified to profit or loss (1,530.00) (1,276.00)
5 Total Other comprehensive income (1,572.00) (1,771.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4,22,396.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4,668.00
Adjustments for decrease (increase) in inventories (18,552.00)
Adjustments for decrease (increase) in trade receivables, current (93,671.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (17,131.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 11,620.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 15,402.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 35,145.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 7,000.00
Adjustments for provisions, current 6,197.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (18,350.00)
Adjustments for dividend income 0.00
Adjustments for interest income 3,778.00
Adjustments for share-based payments 952.00
Adjustments for fair value losses (gains) (3,456.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1,960.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (66,586.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,42,500.00)
Net cash flows from (used in) operations 2,79,896.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 52,442.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,27,454.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 7,956.00
Other cash receipts from sales of equity or debt instruments of other entities 5,39,907.00
Other cash payments to acquire equity or debt instruments of other entities 7,48,813.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 585.00
Purchase of property, plant and equipment 26,165.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 7,000.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 3,635.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (10,267.00)
Net cash flows from (used in) investing activities (2,56,074.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 534.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 70,638.00
Repayments of borrowings 0.00
Payments of lease liabilities 2,995.00
Dividends paid 54,765.00
Interest paid 3,125.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 10,287.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (18,333.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (18,333.00)
Cash and cash equivalents cash flow statement at beginning of period 34,180.00
Cash and cash equivalents cash flow statement at end of period 15,847.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Advance 0.00 Approved 0.00 0.00 198.30
2 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 127.20 73.50
3 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 233.30 146.70
4 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 65.50 90.10
5 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 243.30 129.90
6 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 19.70 36.30
7 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 0.00 1.60
8 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 433.20 394.10
9 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 1,799.40 2,077.50
10 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 2,884.40 3,808.10
11 Lupin Limited Lupin Investments Pvt. Limited Entity having significant influence over the company Any other transaction Creditors 0.00 - 0.00 0.30 0.00
12 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 80.00 254.80
13 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 3,470.70 3,001.10
14 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 4,716.70 5,627.40
15 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 15.10 6.00
16 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 419.80 650.50
17 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 6,209.90 8,147.90
18 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 14,348.90 14,616.30
19 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 0.00 2.00
20 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 1.10 0.00
21 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors 0.00 - 0.00 (348.50) (159.30)
22 Lupin Limited Shuban Prints Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.10 0.10
23 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.00 52.30
24 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 81.00 5.80
25 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors 0.00 - 0.00 0.00 0.60
26 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 3,520.90 4,277.20
27 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 4,457.90 3,991.30
28 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 4,650.50 5,960.80
29 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 20,554.30 13,463.20
30 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 72,770.50 47,161.40
31 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 61.10 90.10
32 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 151.60 1,860.00
33 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 0.00 138.50
34 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 1,302.90 7,700.90
35 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 3,32,445.30 4,40,880.00
36 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 7,096.40 7,589.70
37 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 85.40 20.50
38 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 0.00 2.50
39 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 5,190.30 5,412.20
40 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Debtors 0.00 - 0.00 515.90 0.00
41 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 18.30 0.00
42 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Debtors 0.00 - 0.00 5,008.10 4,323.10
43 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Inter-corporate deposit 0.00 - 0.00 74.00 74.00
44 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Deposits received balance Premises 0.00 - 0.00 30.00 30.00
45 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Deposits received balance Premises 0.00 - 0.00 1.00 1.00
46 Lupin Limited Lupin Human Welfare and Research Foundation Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction CSR Contribution/Expenses 2,404.50 - 2,404.50 0.00 0.00
47 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 28.20 1,805.90
48 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 40.40 (0.60)
49 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 31.50 38.30
50 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 108.90 74.10
51 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 52.00 30.30
52 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 77.50 65.30
53 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 42.80 30.40
54 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 53.40 2,047.10
55 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 12.40 1.60
56 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 480.00 1,091.40
57 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 (16.80) 101.10
58 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 0.00 0.30
59 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 20.30 (47.80)
60 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 664.20 443.30
61 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 0.00 0.10
62 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 (1.70) 22.30
63 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 0.00 299.90
64 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 65.00 137.50
65 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 21.00 24.20
66 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 7.40 19.60
67 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 31.10 63.30
68 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Expenses receivable 0.00 - 0.00 35.90 26.10
69 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Payable 0.00 - 0.00 225.10 530.90
70 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 22.80 0.00 0.00
71 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 66.10 0.00 0.00
72 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - (1.20) 0.00 0.00
73 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 488.20 0.00 0.00
74 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 389.30 0.00 0.00
75 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 172.30 0.00 0.00
76 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 794.30 0.00 0.00
77 Lupin Limited Lupin Investments Pvt. Limited Entity having significant influence over the company Any other transaction Expenses Reimbursed 10.00 Approved 0.50 0.00 0.00
78 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 1,828.70 0.00 0.00
79 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 6.10 0.00 0.00
80 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 214.10 0.00 0.00
81 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - 1,779.50 0.00 0.00
82 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - (7.80) 0.00 0.00
83 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed 0.00 - (1.10) 0.00 0.00
84 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses Reimbursed 100.00 Approved 12.10 0.00 0.00
85 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 326.60 0.00 0.00
86 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 81.30 0.00 0.00
87 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 0.00 - 219.50 0.00 0.00
88 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 63.00 40.50
89 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 14.90 14.30
90 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 172.10 249.90
91 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1.20 0.60
92 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 38.60 38.90
93 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 6.70 7.60
94 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 2.10 2.10
95 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 11.80 12.70
96 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1,116.50 1,564.70
97 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 358.40 483.70
98 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 8.20 17.80
99 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1,099.00 3,510.70
100 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1.30 0.70
101 Lupin Limited Lupin Oncology Inc., USA Subsidiary Any other transaction Income Receivable 0.00 - 0.00 1,844.00 1,361.70
102 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 17.40 81.50
103 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 250.10 653.40
104 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 4.90 4.70
105 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 20.20 36.50
106 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 0.00 82,001.30
107 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 70.50 156.00
108 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Income Receivable 0.00 - 0.00 13.30 14.20
109 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 112.60 119.40
110 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 17.80 45.30
111 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 35.00 33.00
112 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Any other transaction Income Receivable 0.00 - 0.00 2.70 1.90
113 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Interest received 0.00 - 0.70 0.00 0.00
114 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Interest received 0.00 - 501.40 0.00 0.00
115 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Interest received 0.00 - 293.50 0.00 0.00
116 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Investment 0.00 - 0.00 3,28,055.60 3,28,055.60
117 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Investment 0.00 - 0.00 333.20 333.20
118 Lupin Limited Lupin Biologics Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 15.00 15.00
119 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Investment 0.00 - 4,000.00 35,816.70 39,816.70
120 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Investment 0.00 - 2,990.00 15,864.00 18,854.00
121 Lupin Limited Lupin Lanka (Private) Ltd., Sri Lanka Wholly -Owned Subsidiary Investment 0.00 - 0.00 167.50 167.50
122 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Investment 0.00 - 0.00 2,510.00 2,510.00
123 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Investment 0.00 - 0.00 85,950.00 85,950.00
124 Lupin Limited Lupin Oncology Inc., USA Subsidiary Investment 0.00 - 0.00 7,692.80 7,692.80
125 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Investment 0.00 - 0.00 137.90 137.90
126 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Investment 0.00 - 10.00 0.00 10.00
127 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Investment 0.00 - 0.00 6,12,654.50 6,12,654.50
128 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Loan 0.00 - 0.00 12,500.00 12,500.00 Loan 8.00 5 years Unsecured Business Purpose
129 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan 0.00 - 7,000.00 3,000.00 10,000.00 Loan 7.800 12 months Unsecured Business Purpose
130 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 3,144.30 0.00 0.00
131 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 236.20 0.00 0.00
132 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 0.10 0.00 0.00
133 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 16,165.90 0.00 0.00
134 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 5.80 0.00 0.00
135 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 0.50 0.00 0.00
136 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 2,400.00 Approved 670.50 0.00 0.00
137 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 1,836.90 0.00 0.00
138 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 22.90 0.00 0.00
139 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 74.50 0.00 0.00
140 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 142.10 0.00 0.00
141 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 52.30 0.00 0.00
142 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 113.80 0.00 0.00
143 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 58.80 0.00 0.00
144 Lupin Limited Lupin Human Welfare and Research Foundation Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Recoveries 0.10 Approved 0.10 0.00 0.00
145 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 2,018.70 0.00 0.00
146 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 4.30 0.00 0.00
147 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 1,111.00 0.00 0.00
148 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 426.70 0.00 0.00
149 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 2.90 0.00 0.00
150 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - (2.90) 0.00 0.00
151 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 437.90 0.00 0.00
152 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 0.10 0.00 0.00
153 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 34.20 0.00 0.00
154 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 299.90 0.00 0.00
155 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 68.70 0.00 0.00
156 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Recoveries 200.00 Approved 44.00 0.00 0.00
157 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 29.60 0.00 0.00
158 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 62.30 0.00 0.00
159 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Recoveries 0.00 - 54.30 0.00 0.00
160 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Recoveries 100.00 Approved 1.80 0.00 0.00
161 Lupin Limited Mr. Nilesh D. Gupta Key Management Personnel Remuneration 707.50 Approved 707.50 0.00 0.00
162 Lupin Limited Mrs. Manju D. Gupta Non- Executive Directors Remuneration 2.00 Approved 2.00 0.00 0.00
163 Lupin Limited Ms.Vinita Gupta Key Management Personnel Remuneration 1,706.00 Approved 1,706.00 0.00 0.00
164 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent expense 140.00 Approved 60.10 0.00 0.00
165 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 0.00 - 30.00 0.00 0.00
166 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 0.00 - 385.20 0.00 0.00
167 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent Income 25.00 Approved 8.10 0.00 0.00
168 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 9.20 0.00 0.00
169 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Sale of goods or services 0.00 - 19.60 0.00 0.00
170 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Sale of Business Undertaking 0.00 - 1,800.00 0.00 0.00
171 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Sale of Business Undertaking 0.00 - 82,000.00 0.00 0.00
172 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 462.70 0.00 0.00
173 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1,517.60 0.00 0.00
174 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 565.60 0.00 0.00
175 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 8,000.00 Approved 1,732.70 0.00 0.00
176 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 6,851.10 0.00 0.00
177 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 4,570.10 0.00 0.00
178 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 6,846.50 0.00 0.00
179 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 0.00 - 14,280.50 0.00 0.00
180 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 78,930.30 0.00 0.00
181 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 54.90 0.00 0.00
182 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 463.80 0.00 0.00
183 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 0.00 - 319.80 0.00 0.00
184 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 0.00 - 8,561.70 0.00 0.00
185 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2,99,829.30 0.00 0.00
186 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 0.00 - 728.60 0.00 0.00
187 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 126.80 0.00 0.00
188 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1.20 0.00 0.00
189 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 0.00 - 5,897.90 0.00 0.00
190 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 258.50 0.00 0.00
191 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 112.50 0.00 0.00
192 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 239.90 0.00 0.00
193 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 79.50 0.00 0.00
194 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 4.80 0.00 0.00
195 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 1,108.50 0.00 0.00
196 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 950.00 0.00 0.00
197 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 0.80 0.00 0.00
198 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 3,314.90 0.00 0.00
199 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 0.00 - 238.80 0.00 0.00
200 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 500.00 Approved 156.10 0.00 0.00
201 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 1,000.00 Approved 409.90 0.00 0.00
202 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 78.00 0.00 0.00
203 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 32.00 0.00 0.00
204 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 0.00 - 20.40 0.00 0.00
205 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 2.10 0.00 0.00
206 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 76.30 0.00 0.00
207 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 5.40 0.00 0.00
208 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 0.00 - 4.70 0.00 0.00
209 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 0.00 - 25.10 0.00 0.00
210 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 33.10 0.00 0.00
211 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Sale of goods or services 0.00 - 256.90 0.00 0.00
212 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 17.50 0.00 0.00
213 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 0.00 - 852.90 0.00 0.00
214 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1.80 0.00 0.00
215 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 3.00 Approved 0.70 0.00 0.00
216 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 0.00 - 50.50 0.00 0.00
217 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 288.00 0.00 0.00
218 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 0.00 - 11.70 0.00 0.00
219 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 35.80 0.00 0.00
220 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Sale of goods or services 0.00 - 1.20 0.00 0.00
221 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Sale of goods or services 100.00 Approved 32.40 0.00 0.00
222 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Sale of goods or services 0.00 - 14.70 0.00 0.00
223 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 0.00 - 44.40 0.00 0.00
224 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 0.00 - 59.50 0.00 0.00
225 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Sale of goods or services 0.00 - 5.40 0.00 0.00
226 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 5,000.00 0.00 5,000.00
227 Lupin Limited Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited) Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 500.00 500.00
228 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 5,000.00 10,000.00 15,000.00
229 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 2,58,524.10 2,68,586.00
230 Lupin Limited LUPINLIFE Consumer Healthcare Limited Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 5,000.00 0.00 5,000.00
231 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company 0.00 - 0.00 34,593.60 39,069.60
232 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantees issued by the Company on behalf of subsidiary companies for contractual obligations 0.00 - 0.00 57,225.70 59,452.90
233 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Rent Income 0.00 Not Applicable 2.70 0.00 0.00
234 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 5.20 0.00 0.00
235 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Purchase of goods or services 6,000.00 - 850.40 0.00 0.00
236 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 7,865.00 7,874.20
237 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 0.70 0.60
238 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Investment 0.00 Not Applicable 0.00 16,659.50 16,659.50
239 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Purchase of goods or services 0.00 Not Applicable 2.50 0.00 0.00
240 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Purchase of goods or services 0.00 Not Applicable 832.00 0.00 0.00
241 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Reimbursement 0.00 Not Applicable 22.90 0.00 0.00
242 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivable 0.00 Not Applicable 0.00 211.60 604.90
243 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 Not Applicable 0.00 0.30 19.70
244 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Receivable 0.00 Not Applicable 0.00 1,420.40 1,597.90
245 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Trade Receivable 0.00 Not Applicable 0.00 52.60 0.70
246 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Payable 0.00 Not Applicable 0.00 360.90 266.40
247 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Investment 0.00 Not Applicable 0.00 244.00 253.00
248 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Recoveries 0.00 Not Applicable 1.70 0.00 0.00
249 Lupin Australia Pty Limited, Australia Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivable 0.00 Not Applicable 0.00 0.00 15.10
250 Lupin Australia Pty Limited, Australia Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 15.10 0.00 0.00
251 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 2,100.30 0.00 0.00
252 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 410.30 2,484.50
253 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Purchase of goods or services 0.00 Not Applicable 231.70 0.00 0.00
254 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 129.80 374.10
255 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 713.70 0.00 0.00
256 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Product Liability 0.00 Not Applicable 199.90 0.00 0.00
257 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 308.20 0.00 0.00
258 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 274.90 0.00 0.00
259 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 33.80 0.00 0.00
260 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 61.50 0.00 0.00
261 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 197.20 0.00 0.00
262 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 56.00 0.00 0.00
263 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 455.80 0.00 0.00
264 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 21,126.80 0.00 0.00
265 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 156.00 0.00 0.00
266 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 3.20 0.00 0.00
267 Lupin Research Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 9.30 0.00 0.00
268 Lupin Research Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 0.30 0.00 0.00
269 Lupin Research Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 3.10 0.00 0.00
270 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 4,026.00 0.00 0.00
271 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 28,928.40 0.00 0.00
272 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 15.10 0.00 0.00
273 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Purchase of goods or services 0.00 Not Applicable 52.60 0.00 0.00
274 Novel Laboratories, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 423.50 0.00 0.00
275 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 2.00 0.00 0.00
276 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 36.20 0.00 0.00
277 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 279.60 0.00 0.00
278 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 622.70 0.00 0.00
279 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 21.60 0.00 0.00
280 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Sale of goods or services 200.00 - 13.80 0.00 0.00
281 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 100.00 - 25.90 0.00 0.00
282 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 2,050.00 0.00 0.00
283 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 89.00 0.00 0.00
284 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 46.00 0.00 0.00
285 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 2,18,461.50 0.00 0.00
286 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 677.40 0.00 0.00
287 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 459.80 0.00 0.00
288 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 0.10 0.00 0.00
289 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 83.70 0.00 0.00
290 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 13,195.10 0.00 0.00
291 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 1.90 0.00 0.00
292 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 151.60 0.00 0.00
293 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 756.10 0.00 0.00
294 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 51.80 0.00 0.00
295 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 94.70 0.00 0.00
296 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 3,816.80 0.00 0.00
297 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 157.40 0.00 0.00
298 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 329.60 0.00 0.00
299 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 0.00 Not Applicable 47.70 0.00 0.00
300 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Sale of goods or services 200.00 - 26.20 0.00 0.00
301 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 83.70 0.00 0.00
302 Lupin Management, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 236.10 0.00 0.00
303 Lupin Management, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 199.80 0.00 0.00
304 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 64.70 0.00 0.00
305 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 43.40 0.00 0.00
306 Lupin Management, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 279.30 0.00 0.00
307 Lupin Management, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 195.00 0.00 0.00
308 Lupin Management, Inc., USA Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 16.40 0.00 0.00
309 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 129.30 144.00
310 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 721.30 136.70
311 Lupin Research Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 1.00 0.00
312 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 2.50 0.80
313 Lupin Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 115.10 0.00
314 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 121.60 900.90
315 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 1,126.30 1,617.00
316 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 7,712.80 28,605.50
317 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 0.00 0.50
318 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 29.00 24.30
319 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 109.40 44.20
320 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 50.00 10.70
321 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 43.90 45.00
322 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 111.60 182.40
323 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 35.40 19.30
324 Lupin Management, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 265.70 127.00
325 Lupin Management, Inc., USA Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 31.30 49.30
326 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 323.70 723.50
327 Lupin Management, Inc., USA Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 50.00 0.00
328 Lupin Pharmaceuticals, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 81.30 84.40
329 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 179.60 24.00
330 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 51.70 156.10
331 Lupin Research Inc., USA Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 552.30 0.00
332 Novel Laboratories, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 71.70 124.30
333 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 20.90 20.40
334 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 1,352.80 120.90
335 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 11.20 26.60
336 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 1,31,559.60 1,50,923.60
337 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 32,093.10 37,121.40
338 Lupin Research Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 0.00 9.50
339 Lupin Research Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 0.00 3.20
340 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables 0.00 Not Applicable 0.00 0.00 54.00
341 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables 0.00 Not Applicable 0.00 0.00 22.20
342 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Loan 0.00 Not Applicable 0.00 9,860.40 9,860.40 Loan 0 1 Unsecured Business purpose
343 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Investment 0.00 Not Applicable 0.00 37,837.40 37,837.40
344 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Investment 0.00 Not Applicable 0.00 6,104.20 6,104.20
345 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Investment 0.00 Not Applicable 0.00 7,691.00 7,691.00
346 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Investment 0.00 Not Applicable 0.00 61,725.70 61,725.70
347 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction BUSINESS DEVELOPMENT/COMPLIANCE 0.00 Not Applicable 0.60 0.00 0.00
348 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction TRADE PAYABLES 0.00 Not Applicable 0.00 0.50 0.20
349 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 1,462.10 1,514.80
350 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 2.30 (2.60)
351 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 11.30 9.70
352 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 537.70 1,338.60
353 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 30.20 131.50
354 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 266.60 709.40
355 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 16,045.00 17,827.90
356 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 1,095.70 3,180.10
357 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 21.20 21.40
358 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 49.20 38.70
359 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 22.40 62.10
360 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 581.80 21.60
361 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 180.60 58.30
362 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 88.10 95.30
363 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 243.60 220.60
364 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 53.80 60.00
365 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 52.00 136.90
366 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 1,063.80 622.40
367 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 12.30 8.20
368 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 221.80 223.90
369 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 3.40 0.00
370 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan 0.00 Not Applicable 3,221.90 6,840.50 3,618.60 Loan 5.00 9 yrs Unsecured Business Purpose
371 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Loan 0.00 Not Applicable 4,207.20 18,801.90 23,009.10 Loan 3.7500 3 yrs Unsecured Business Purpose
372 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Loan 0.00 Not Applicable 0.00 20,995.00 22,681.40 Loan 5.500 2 yrs Unsecured Business Purpose
373 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan 0.00 Not Applicable 0.00 22,220.40 23,737.50 Loan 4.500 3 yrs Unsecured Business Purpose
374 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Investment 0.00 Not Applicable 0.00 61,495.50 61,495.50
375 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Investment 0.00 Not Applicable 0.00 1,726.20 1,726.20
376 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Investment 0.00 Not Applicable 0.00 2,797.50 2,797.50
377 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Investment 0.00 Not Applicable 0.00 2,507.60 2,507.60
378 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Investment 0.00 Not Applicable 0.00 9,170.10 9,170.10
379 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment 0.00 Not Applicable 0.00 41,702.50 41,702.50
380 Lupin Atlantis Holdings SA, Switzerland Lymed S.A.S., France Fellow Subsidiary Investment 0.00 Not Applicable 0.00 9,170.10 9,170.10
381 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Interest received 0.00 Not Applicable 130.80 0.00 0.00
382 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Interest received 0.00 Not Applicable 607.00 0.00 0.00
383 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Interest received 0.00 Not Applicable 358.20 0.00 0.00
384 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received 0.00 Not Applicable 460.60 0.00 0.00
385 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction income receivable 0.00 Not Applicable 0.00 149.00 0.00
386 Lupin Atlantis Holdings SA, Switzerland Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 963.60 0.00 0.00
387 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 1,373.40 0.00 0.00
388 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 755.20 0.00 0.00
389 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 10,769.90 0.00 0.00
390 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 1,982.10 0.00 0.00
391 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 100.80 0.00 0.00
392 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 85.60 0.00 0.00
393 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 22.60 0.00 0.00
394 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 45.50 0.00 0.00
395 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Other Income 0.00 Not Applicable 254.90 0.00 0.00
396 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 37.80 0.00 0.00
397 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 91.90 0.00 0.00
398 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction income receivable 0.00 Not Applicable 0.00 86.80 0.00
399 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 154.80 0.00 0.00
400 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 39.80 0.00 0.00
401 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 721.30 0.00 0.00
402 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 335.60 0.00 0.00
403 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 257.20 0.00 0.00
404 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 419.30 0.00 0.00
405 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 1,496.70 0.00 0.00
406 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 371.40 0.00 0.00
407 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 13.80 0.00 0.00
408 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 0.00 Not Applicable 184.80 0.00 0.00
409 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Loan 0.00 Not Applicable 91.70 690.70 782.40 Loan 0.7500 2 yrs Unsecured Business Purpose
410 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 95.60 103.90
411 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables 0.00 Not Applicable 0.00 96.70 140.20
412 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Interest received 0.00 Not Applicable 10.50 0.00 0.00
413 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Sale of goods or services 0.00 Not Applicable 215.40 0.00 0.00
414 Hormosan Pharma GmbH, Germany Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Receivables 0.00 Not Applicable 0.00 0.20 0.00
415 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan 0.00 Not Applicable 266.10 6,837.00 7,103.10 Loan 4.00 3 yrs Unsecured Business Purpose
416 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received 0.00 Not Applicable 200.00 0.00 0.00
417 Nanomi B.V., Netherlands Generic Health Pty Limited, Australia Fellow Subsidiary Investment 0.00 Not Applicable 0.00 11,886.70 11,886.70
418 Nanomi B.V., Netherlands Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Investment 0.00 Not Applicable 0.00 68,787.80 68,787.80
419 Nanomi B.V., Netherlands Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Investment 0.00 Not Applicable 0.00 2,505.60 2,505.60
420 Nanomi B.V., Netherlands Lupin Mexico S.A. de C.V., Mexico Fellow Subsidiary Investment 0.00 Not Applicable 0.00 521.50 64.50
421 Nanomi B.V., Netherlands Lupin Philippines, Inc., Philippines Fellow Subsidiary Investment 0.00 Not Applicable 0.00 598.90 598.90
422 Nanomi B.V., Netherlands Generic Health SDN. BHD., Malaysia Fellow Subsidiary Investment 0.00 Not Applicable 0.00 104.90 0.00
423 Nanomi B.V., Netherlands Lupin Inc., USA Fellow Subsidiary Investment 0.00 Not Applicable 0.00 6,72,687.60 6,72,687.60
424 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment 0.00 Not Applicable 0.00 13,167.10 13,167.10
425 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction income receivable 0.00 Not Applicable 0.00 68.40 0.00
Total value of transaction during the reporting period 9,26,977.50